title: Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.
abstract: Cl-992, a novel potent inhibitor of primate renin, was tested for blood pressure-lowering efficacy in sodium-restricted, furosemide-treated conscious normotensive cynomolgus monkeys and conscious renal hypertensive monkeys. The hypertensive monkey model provided an opportunity to determine the response to a renin inhibitor in a pathological nonhuman primate model of hypertension without concurrent diuretic treatment or dietary sodium restriction and on repeated oral administration. Cl-992 has IC50 values of 0.58 +/- 0.06 (n = 4) and 0.36 +/- 0.03 nM (n = 8) against human and monkey renin, respectively. In normotensive monkeys, oral Cl-992 at doses of 3, 10 and 30 mg/kg reduced mean arterial blood pressure (MABP) by 8 +/- 2, 15 +/- 7 and 29 +/- 7 mm Hg (n = 5 animals per dose level, P < .05), respectively (base line, 103 +/- 3 mm Hg). Intravenous Cl-992 (0.0001 to 0.1 mg/kg) also caused dose-dependent decreases in MABP and a maximum reduction of 23 +/- 4 mm Hg. The decrease in MABP after Cl-992 was paralleled by an inhibition of plasma renin activity (PRA) and a reduction in immunoreactive angiotensin II. In renal hypertensive monkeys, oral Cl-992 at doses of 3, 10 and 30 mg/kg reduced MABP by 6 +/- 2, 18 +/- 6 and 37 +/- 8 mm Hg (n = 3 or 4, P < .05), respectively (base line, 134 +/- 4 mm Hg).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan.
authors.forename: M J
authors.initials: MJ
authors.lastname: Ryan
authors.forename: G W
authors.initials: GW
authors.lastname: Hicks
authors.forename: B L
authors.initials: BL
authors.lastname: Batley
authors.forename: S T
authors.initials: ST
authors.lastname: Rapundalo
authors.forename: W C
authors.initials: WC
authors.lastname: Patt
authors.forename: D G
authors.initials: DG
authors.lastname: Taylor
authors.forename: J A
authors.initials: JA
authors.lastname: Keiser
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy; D008252:Macaca fascicularis; D008297:Male; D051381:Rats; D012083:Renin / Q000097:blood; D000092502:Renin Inhibitors
chemical_list: D000959:Antihypertensive Agents; D004151:Dipeptides; D012083:Renin; D000092502:Renin Inhibitors; C085688:CI 992